|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we propose that lysosomal TM4SF5 senses and enables arginine efflux for mTORC1/S6K1 activation, and arginine-auxotroph in hepatocellular carcinoma may be targeted by blocking the arginine sensing using anti-TM4SF5 reagents.
|
30956113 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of the present study demonstrated that low TM4SF5 expression was associated with tumor malignant progression and may be a good prognostic biomarker for OS in HCC.
|
31186734 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunization with a peptide vaccine targeting human TM4SF5 has been shown to exert prophylactic and therapeutic effects against the development of hepatocellular carcinoma and colon cancer in mouse models.
|
29749436 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The transmembrane four L6 family member 5 (TM4SF5) protein is a novel molecular target for the prevention and treatment of hepatocellular carcinoma.
|
28255353 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, it remains unknown how TM4SF5 in hepatocellular carcinoma cells compromises with immune actions initiated by extracellular cytokines.
|
24912675 |
2014 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our work offers a preclinical proof of concept for TM4SF5 as a promising target for antibody therapeutics to treat HCC.
|
24802189 |
2014 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we have shown that immunization with TM4SF5 peptide-CpG-DNA-liposome complex induces production of TM4SF5-specific antibodies and protects mice from HCC progression in an allograft model.
|
23624388 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Wildtype (WT) TM4SF5 expression enhanced migration and invasive protrusion formation in a c-Src-dependent manner, compared with TM4SF5-null control hepatoma cell lines.
|
23220047 |
2013 |
|
Calcification of coronary artery
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis.
|
22916037 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tetraspan TM4SF5-dependent direct activation of FAK and metastatic potential of hepatocarcinoma cells.
|
23077174 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that our improved peptide vaccine technology provides a novel prophylaxis measure as well as therapy for HCC patients with TM4SF5-positive tumors.
|
22427965 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, these observations suggest that TSAHC may be a promising anti-tumorigenic reagent, especially against TM4SF5-mediated hepatocarcinoma.
|
21099346 |
2011 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We previously reported that the four-transmembrane L6 family member 5 (TM4SF5) was highly expressed in hepatocarcinoma, induced morphological elongation and epithelial-mesenchymal transition, and caused abnormal cell growth in multilayers in vitro and tumor formation in vivo.
|
19177595 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, tumors from nude mice injected with TM4SF5-expressing cells and from clinical human hepatocarcinoma tissues showed enhanced integrin alpha(5) expression, vessel formation, and signaling activity, which were inhibited by administration of anti-integrin alpha(5) or -VEGF antibody.
|
19036703 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our observations have revealed a role for TM4SF5 in causing uncontrolled growth of human hepatocarcinoma cells through EMT.
|
18357344 |
2008 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In addition, TM4SF5 expression was significantly associated with tumor size, vascular invasion, tumor differentiation, and tumor-node-metastasis stage.
|
31186734 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
No association was observed between TM4SF5 expression and clinicopathological characteristics, apart from tumor depth of invasion (P=0.027).
|
29749436 |
2018 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
TM4SF5-mediated EMT contributes to diverse cellular functions, leading to fibrotic phenotypes and initiating and maintaining tumors in primary and/or metastatic regions, in addition to its role in muscle development in zebrafish.
|
26404468 |
2015 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Robust production of TM4SF5-specific antibodies was induced by challenge with CT-26 cells and the tumor growth was significantly suppressed in the immunized mice.
|
23624388 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
These results suggest that our improved peptide vaccine technology provides a novel prophylaxis measure as well as therapy for HCC patients with TM4SF5-positive tumors.
|
22427965 |
2012 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In this study, TSAHC and two derivatives showed similar antagonistic activities against TM4SF5-mediated signaling and multilayer growth in vitro and anti-tumorigenic activity even in early stages of TM4SF5-mediated tumor formation in nude mice.
|
21099346 |
2011 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Tumor formation in nude mice injected with TM4SF5-expressing cells and the growth of cells expressing endogenous TM4SF5, but not of TM4SF5-null cells, was suppressed by treatment with TSAHC, but not by treatment with its analogs.
|
19177595 |
2009 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Tetraspan TM4SF5 is highly expressed in a diverse number of tumor types.
|
19036703 |
2009 |